Toripalimab for High-risk Locally Advanced Cervical Cancer
Toripalimab Combined With Chemoradiotherapy Followed by Toripalimab Maintenance Therapy for High-risk Locally Advanced Cervical Cancer: the Phase II Single-arm TorCH -CC Study
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Listed as NCT06416696, this PHASE2 trial focuses on Cervical Cancers and remains ongoing. Sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, it has been updated 5 times since 2024, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
5 versions recorded-
Feb 2026 — Present [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jan 2026 — Feb 2026 [monthly]
Recruiting PHASE2
-
Sep 2024 — Jan 2026 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE2
First recorded
Jan 2024
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
For direct contact, visit the study record on ClinicalTrials.gov .